Literature DB >> 12145554

Effects of the nitric oxide donor molsidomine on the early stages of liver damage in rats with bile duct ligation: a biochemical and immunohistochemical approach.

H Oztürk1, Y Yağmur, H Buyukbayram, A I Dokucu, A Gurel.   

Abstract

This study aimed to evaluate the effects of the nitric oxide donor molsidomine on the early stages of liver damage and biochemical changes in rats with bile duct ligation (BDL). Forty prepubertal male Sprague-Dawley rats weighing 125-140 g were studied. Group 1 rats (sham-control, n = 10) were not subjected to any surgical manipulation. Group 2 rats (BDL/untreated, n = 10) were subjected to BDL but no drug was administered. Group 3 rats (BDL/L-NAME, n = 10) received a daily dose of N(G)-nitro-L-arginine methyl ester (L-NAME) intraperitoneally for 7 days after BDL. Group 4 rats (BDL/molsidomine, n = 10) received a daily dose of molsidomine by gastric tube for 7 days after BDL. After 1 week, biochemical and histological evaluations were performed and the liver hydroxyproline content was measured. Serum bilirubin and liver enzymes were significantly increased in the BDL/untreated, BDL/L-NAME and BDL/molsidomine groups in comparison with the sham-control group 1 week after BDL. However, the liver enzymes were significantly decreased in the BDL/molsidomine group in comparison with the BDL/untreated and BDL/L-NAME groups. In the BDL/L-NAME group, proliferation of portal and periportal biliary ductules with disorganization of the hepatocyte plates, dilated portal spaces and areas of polymorphonuclear leukocyte infiltration, fibrosis and hepatocyte necrosis were observed. In the BDL/molsidomine group, polymorphonuclear leukocyte infiltration, hepatocyte necrosis and fibrosis were rarely seen. The hydroxyproline content in the liver was increased 1 week after obstruction in the BDL/untreated and BDL/L-NAME groups when compared to BDL/molsidomine group. Collagen type-IV expression was not observed in the BDL/molsidomine group in contrast to the BDL/untreated and BDL/L-NAME groups. In conclusion, during 1 week of treatment, the nitric oxide donor molsidomine improved hepatic fibrosis in the hepatic parenchyma and did not affect serum bilirubin values, but positively affected the serum aspartate aminotransferase and alanine aminotransferase values. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145554     DOI: 10.1159/000063069

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  3 in total

1.  Oxidative stress in portal hypertension-induced rats with particular emphasis on nitric oxide and trace metals.

Authors:  Titiz Izzet; Krand Osman; Unal Ethem; Yavuz Nihat; Kusaslan Ramazan; Dogan Mustafa; Uzun Hafize; Kiziler Ali Riza; Aydemir Birsen; Genc Habibe; Aydin Seval; Simsek Gonul
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

2.  Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-β1 therapies in inducible nitric oxide synthase-deficient mice.

Authors:  Monica G Ferrini; Joanne Moon; Steve Rivera; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  BJU Int       Date:  2011-08-18       Impact factor: 5.588

3.  The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate.

Authors:  Chao Wang; Barbara K Kemp-Harper; Martina Kocan; Sheng Yu Ang; Tim D Hewitson; Chrishan S Samuel
Journal:  Front Pharmacol       Date:  2016-03-31       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.